- Home
- ONVO vs INM Comparison
ONVO vs INM Comparison
Compare ONVO & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONVO
- INM
- Stock Information
- Founded
- ONVO 2007
- INM 1981
- Country
- ONVO United States
- INM Canada
- Employees
- ONVO N/A
- INM N/A
- Industry
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- ONVO Health Care
- INM Health Care
- Exchange
- ONVO Nasdaq
- INM Nasdaq
- Market Cap
- ONVO 3.0M
- INM 3.2M
- IPO Year
- ONVO N/A
- INM N/A
- Fundamental
- Price
- ONVO $1.87
- INM $3.00
- Analyst Decision
- ONVO
- INM
- Analyst Count
- ONVO 0
- INM 0
- Target Price
- ONVO N/A
- INM N/A
- AVG Volume (30 Days)
- ONVO 347.1K
- INM 56.6K
- Earning Date
- ONVO 05-30-2025
- INM 05-13-2025
- Dividend Yield
- ONVO N/A
- INM N/A
- EPS Growth
- ONVO N/A
- INM N/A
- EPS
- ONVO N/A
- INM N/A
- Revenue
- ONVO $122,000.00
- INM $4,832,013.00
- Revenue This Year
- ONVO $59.08
- INM N/A
- Revenue Next Year
- ONVO $18.24
- INM N/A
- P/E Ratio
- ONVO N/A
- INM N/A
- Revenue Growth
- ONVO N/A
- INM N/A
- 52 Week Low
- ONVO $1.56
- INM $1.72
- 52 Week High
- ONVO $21.96
- INM $15.70
- Technical
- Relative Strength Index (RSI)
- ONVO 37.84
- INM 62.76
- Support Level
- ONVO $1.56
- INM $2.56
- Resistance Level
- ONVO $1.78
- INM $3.05
- Average True Range (ATR)
- ONVO 0.24
- INM 0.27
- MACD
- ONVO 0.13
- INM 0.09
- Stochastic Oscillator
- ONVO 43.06
- INM 92.98
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.